Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), ...

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

Regulus Therapeutics Inc has a consensus price target of $7.71 based on the ratings of 7 analysts. The high is $11 issued by Canaccord Genuity on April 30, 2025.The low is $3 issued by Wells Fargo ...

The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Novartis today announced that its previously announced tender offer (the "Offer") by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...